C Ascorbate was formulated as a mineral transporter based on results of studies by Hans Neiper, M.D., of West Germany and other researchers. A seven year study by Dr. Neiper concluded that a 50/50 mixture of potassium and magnesium aspartates decreased the death rate from myocardial infarct by 84%. These results were confirmed by an Australian study.

An important factor in overcoming myocardial muscular fatigue and subsequent potential muscular necrosis in the myocardium, and overcoming an overspill of the lactic acid pool, is to increase the formation of ATP. Aspartic acid transports the potassium and magnesium ions to the inner layer of the outer cell membrane which activates the respective enzymes, resulting in increased formation of ATP..⁽¹⁾

It is well known that a high potency intake of mineral ascorbates increases urinary excretion of several minerals, chiefly calcium and magnesium. The ascorbate bonding of calcium is of prime importance for the removal of unwanted mineral deposits. Additional minerals have been added to insure that proper mineral levels are maintained. Ascorbated minerals are partially bound and partially electrostatically associated which assures their availability.

Calcium and sodium ascorbates have been intentionally left out of this formula. Calcium should be monitored by the health care professional and administered in the proper form as required.⁽²⁾

Recent studies show that failure of the natural pacemaker system of the heart can be substantially reduced by administering selenium. It is further stated that 90% of all pacemaker implants would be superfluous if adequate selenium were administered.

Studies of certain areas of China, Finland and the Unites States where the soil is selenium poor showed heart diseases and death from heart attack to be far above the average for other areas of these countries. Adding selenium to the diets of people in these areas significantly reduced the incidence of heart attackck.⁽³⁾

Research indicates that Vitamin C helps to prevent blood clots. One study has shown that patients given two grams of Vitamin C daily had fewer adhesive platelets. In other tests with patients suffering from heart disease, Vitamin C was found to increase fibrinolytic activity by over 60%, even though none of the patients was deficient in Vitamin C. Further studies reveal that treatment with Vitamin C will lower LDL and increase HDL concentration and also stimulate the production of the enzyme LPL (lipotrophic lipase) which acts as a cleansing agent on the vascular walls.⁽⁴⁾

This quality product can be used wherever a potent Vitamin C product is required and can be tailored to just about any potency needed.

Nutritional supplements for effective cardiovascular support:

C Ascorbate: 1 teaspoon (5100 mg.) 3 times daily dissolved in water or juice.

CoQ10 (Co-Enzyme Q10): 400 mg. or more daily

WARNING: This publication and the product contained herein have not been approved or evaluated by the Food and Drug Administration. This publication, and the product contained herein are not intended to diagnose, treat, cure or prevent any disease. The product relates to nutritional support only.

1. Symposium on Magnesium, Stuttgart-Hohenheim (1977)

Neiper, H.A., M.D., International Academy of preventive Medicine Paper (1984)

Neiper, H.A. and Blumberger, K., The Effectiveness of Electrolyte Carrier Compounds on Myocardial Metabolism, Illustrated by Magnesium and Potassium Aspartate, Artzl. Forsch. 15:305-309 (1961)

Neiper, H.A., Experimental Bases and Clinical Use of Electrolyte Carrier Compounds. Artzl Forsch. 15:510-514 (1961)

Neiper, H.A. and Kohler, L., Investigation of Potassium and Magnesium Nicotinylaspartate. Artzl. Forsch. (1966)

Neiper, H.A. and Kohler, L., Investigation of Potassium and Magnesium 2—Aminoethylphosphate, Arztl Forsch. 16:641 (1962)

Gould, S.E., Pathology of the Heart (Thomas, Springfield 1953)

Hort. W., Pathological Anatomy of Heart Infarct, Med. Welt. 34:1641-1645 (1960)

Gundersen, P., Acute Myocardial Infarct in a Medical Department in the Years 1925-1927 Compared with the Year 1954; cit. Schmuderich, B., Artzl. Forsch. 16:179-184 (1962)

Fromen, R., Modern Data on French Coronary Pathology. Principally a statistical study. Acta. Cardio., 14:39-42 (1959)

Selye, H. Chemical Prevention of Cardiac Necroses (Ronald Press, New York, 1958)

Agranat, A., Magnesium Therapy for Heart Infarction, Med. Proc. (SA) 4:67-69 (1958)

Brown, W.E., Letters to the Editor: Magnesium Sulphate in the Treatment of Angina, Lancet 7215:1313-1315 (1961)

Malkiel-Shapiro, B. and Bersohn, I., Magnesium Sulphate in Coronary Thrombosis, Notes and Comments, Brit. Med. J., 600:292 (1960)

Parsons, R.S., Butler, T. and Sellars, E., Magnesium Sulphate Therapy of Coronary Thrombosis., Med. Proc. (Brit. Med. Assn.) 5:487-488 (1959)

Teeger, A., Antithrombotic Activity of Magnesium Salts, Med. Proc. (Brit Med. Assn.) 4:77-78 (1958)

Koiler, U., Magnesium Prophylaxis of Heart Infarct. Arztl. Forsch. 14:513-517 (1960)

Weber, B., Experimental and Clinical Study of Aspartic Acid Salts (Foulton, Paris 1960)

Lamarch, M., Royer, R. and Bas, M., A comparison between the Activity of the Aspartates and of the Nicotinic Ester of Diethylaminoethanol on Cardiac Manifestations of Acute Hypoxia. C.R. Soc. Biol. CLVI:2099-2101 (1963)

Greef, K., The Action of Potassium and Magnesium Aspartates on the Glycoside Intoxication of the Heart, Proc. Germ. Soc. Pharmacol., April, 1963

Hilmer, W. and Kohler, A., Electrocardiographic Patterns of the ST-T Waves in Disorders of Potassium Metabolism, Med. Welt. 12:565-567 (1961)

Hartert, H., Anticoagulant Treatment of Myocardial Infarction, Med. Welt. 5:251-254 (1962)

Pillen D., The Pathogenesis, Prophylaxis and Therapy of Myocardial Infarct. Med. Klin. 33:1413-1418 (1962)

Nakahara, M., Yamada, S., Sakahashi, H., Nakamishi, Y., Tokita, T. and Yoshihara, T., Antifatigue Effect of Potassium Magnesium Salt of Aspartic Acid on Skeletal Muscels its Mechanism of Action, Agressologie, 5:245-255 (1964)

Bajusz, E., Nutritional Factors in the Pathogenesis of Cardiac Necroses, Z Ernahrungsw. 2:229; 3:1 (1962)

2. Horsey, J., Livesley, B and Dickerston, J.W.T., Ischaemic Heart Disease and Aged Patients: Effects of Ascorbic Acid on Lipoproteins. Journal of Human Nutrition 35:53-58 (1981)

Geoly, K. and Diamond, L.H., Ascorbic Acid and Hypertriglyceridemia, Ann. Int. Med. 93:551 (1980)

John A. colwell and Kay E. Sarji, Veterans Hospital, Charleston S.C.

Alfredo Lopez, Louisiana State University School of Medicine

3. Neiper, H.A., Hanover West Germany, International Academy of Preventive Medicine (1984)

Shamberger, R.J. et. al., Selenium and Other Trace Metal Intakes and Heart Disease in 25 Countries. Twelfth Annual Conference on Trace Substances in Environmental Health, Columbia, MO (1978)

Shamberger, R.J., Selenium in Health and Disease, Symposium on Selenium-Tellurium in the Environment, University of Notre Dame, Indiana, May 1976, p.253-267

Shamberger, R. J. Selenium in Health and Disease, Executive Health (March, 1979)

Salonen, J.T., Alfthan, G., Huttunen, J.K., et. al. Association between Cardiovascular and Myocardial Infarction and Serum Selenium in a Matched Pair Longitudinal Study, Lancet, July 24:175-179 (1982)

Jaakkola, Kaarlo, M.D., University of Jyvaskyla, Finland

Andrews, Jim, Ph.D.; Hames, C.G., M.D. and Mets, J.C. Jr., M.D., Community Cardiovascular Council, Savannah Georgia.

Yang, G.Q., Ph.D., Chinese Academy of Medical Sciences, Peking, China (1973)

4. Ginter, et. al., Effect of Ascorbic Acid on Plasma Cholesterol in Humans in a Long Term Experiment, Int. J. Vit. Nutr. Res., 1977:47

Turlery, West and Horton, Role of Ascorbic Acid in the Regulation of Cholesterol Metabolism and the Pathogenesis of Atherosclerosis. Atherosclerosis 24:18 (1976)

Bates, G.L. HDL Cholesterol and Vitamin C Status, Lancet, p. 661 Sept. 17, 1977.

Leslie, C., M.D., Cambridge, England, Lancet.

Product No. 851 Fill Size: 8 oz. Powder

Dissolves easily in water or juice. Each teaspoon (5100 mg.) provides: % Daily Value

Vitamin C 4000 mg. 6666%
Magnesium Ascorbate 3720 mg.
Magnesium Aspartate 105 mg.
(Elemental magnesium from above 250 mg.) 62%
Potassium Ascorbate 420 mg.
Potassium Aspartate 103 mg.
(Elemental potassium from above 96 mg.) 3%
Zinc Ascorbate 192 mg.
(Elemental zinc from above 30 mg.) 200%
Manganese Ascorbate 30 mg.
(Elemental manganese from above 4.2 mg.) 210%
Selenium Ascorbate 270 mcg.
(Elemental selenium from above 50 mcg.) 71%

RECOMMENDED DOSAGE:
Therapeutic - 1 tsp. 3 times daily or more as directed by a doctor.
Maintenance - 1/3 tsp. 3 times daily or 1 tsp. daily.

NOTE: Vitamin C as mineral ascorbates has a somewhat higher pH than does ascorbic acid alone. This higher pH gives it a somewhat better bowel tolerance. This can be improved upon by starting with a lower dose and gradually increasing it over a period of time.